CABLIVI is the first and only FDA-approved treatment for adults with aTTP/iTTP in combination with plasma exchange and immunosuppression
See the stories of real people, real patients treated with CABLIVI
Follow their personal journey from diagnosis to living with acquired/immune-mediated thrombotic thrombocytopenic purpura (aTTP/iTTP). Every experience is unique and individual results with CABLIVI may vary. These patients were compensated for their time creating these videos. Remember, your doctor is your best source of information, and be sure to ask your doctor any questions you may have.
Meet Alex
“My main concern was bringing up my platelet counts. So learning that CABLIVI, along with immunosuppressive therapy and plasma exchange, could [potentially] help bring my platelet count to a normal level faster, it’s like, ‘OK, let’s do this.’”
Alex, real patient. Individual results may vary. Alex is being compensated by Sanofi.
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. Please stay tuned for the Important Safety Information at the end of this video.
My name is Alex.
*Alex was compensated for his time in the creation of this video.*
I am a husband, I’m a father, I’m a musician. And two years ago, I was diagnosed with aTTP.
My first experience with aTTP was pretty scary. I was on my way to work, and then half of my body went numb. So, I drove myself to the urgent care, and they basically said, “It sounds like you had a ministroke. You might want to go to the ER because there’s nothing we can do for you.”
The first time I was in the hospital, I had a very extended stay. Not knowing what’s wrong with you is just so frightening. You know they’re testing for so many things, and everything comes back negative.
My platelet count kept going down, it just wasn’t improving. Having all these doctors around you, that look kind of concerned because they can’t figure out what’s wrong with you. You sort of want to keep hope, but you somehow also start beginning to lose hope. All you can do is just be patient and hope they figure it out.
They finally diagnosed me with aTTP. I just felt so relieved that they finally figured out what was wrong. On my second experience with aTTP, my new doctor mentioned that there was a medication that could be helpful for me called CABLIVI.
Once I had aTTP again, my main concern was bringing up my platelet counts. So, learning that CABLIVI, along with immunosuppressants and plasma exchange, could help platelet count to a normal level faster, it’s like OK, let’s do this. What do we do? What’s the treatment plan?
The only thing I could think about then was just being home with my family, with my music career. I just wanted things back the way they were.
Within 3 days of starting CABLIVI, my platelet count returned to a normal level. After 7 days, I was well enough to go home.
*CABLIVI was tested in a clinical study of 145 adults with aTTP/iTTP. 72 people were given CABLIVI, plasma exchange (PEX), and immunosuppressive therapy vs 73 people who were given placebo (an injection without any medicine), PEX, and immunosuppressive therapy. Both groups received either CABLIVI or placebo after their daily PEX, and then for 30 days after. Some people received more treatment (up to 28 additional days) based on their doctor’s decision. After treatment was stopped, everyone was followed by their doctor for 28 more days.*
My doctor explained that taking CABLIVI had certain side effects, but thankfully I didn’t experience any.
*The most common side effects include nosebleed, headache and bleeding gums. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.*
Once I was released from the hospital and I continued my medication at home, I had no issues with self-injecting, the nurses at the hospital showed me how to do it, and I was confident that I could do it at home.
I didn’t have any relapses during my CABLIVI treatment, or for 28 days after.
*Significantly fewer people had another episode of aTTP/iTTP that required starting PEX again within the full study period (while taking CABLIVI and 28 days after stopping CABLIVI) in the CABLIVI group vs the placebo group: 13% receiving CABLIVI (9 people) vs 38% receiving placebo (28 people). Individual results may vary.*
So my life today is just staying on top of my symptoms. I just feel more confident and I was ready to move forward with my life. Appreciate my family, and my music career. I can do the things that I wanted to do, and still live a fulfilling life. Even if I'm living with aTTP.
This was Alex's personal experience with CABLIVI. Every patient's experience is unique and individual results will vary. If you're interested in learning more, please speak with your doctor about the potential benefits and risks of treatment with CABLIVI and whether CABLIVI may be right for you.
INDICATION AND IMPORTANT SAFETY INFORMATION
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Who should not take CABLIVI?
Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
Meet Heather
“Even though I know a relapse is possible at any time, I’m confident in knowing that CABLIVI will be there.”
Heather, real patient. Individual results may vary. Heather is being compensated by Sanofi.
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. Please stay tuned for the Important Safety Information at the end of this video.
My name is Heather and this is my aTTP journey.
*Heather was compensated for her time in the creation of this video.*
I’m a teacher’s assistant. A softball coach for the girl’s 7th- and 8th-grade teams.
I really love camping. It gives me a sense of enjoying the outdoors. I spend as much time outside as I can.
In 2007, I became ill. It was a very long, hard diagnosis. I had a very bad menstrual cycle. I went to the doctor and had some tests. They said everything was fine and put me on birth control to stop the bleeding.
A few days later the bleeding had still not stopped. I went out to the local hospital, had labs again. My platelet level was at 9,000, which is extremely low.
They had said that I was going to need to stay in the hospital for a while and get some more tests.
I was very frightened. I wondered if I was going to make it. I didn’t know what I was going to do for living my life.
So it was very, very discouraging for my family and I to wake up every day and not get the answers that we needed.
I had been there for a week and I took a nap. When I woke up from my nap I could not hear. I could not speak. I could not see, and I could not walk.
So I was transported to the larger hospital. I was diagnosed with aTTP.
The treatment for aTTP is very stressful and it takes a lot out of you, especially the older you get.
I was released and sent home. At my 6-month check-up everything was fine. But unfortunately, a week later, I relapsed.
Relapsing 4 or 5 times in 1 year, that was difficult on my body. Difficult on my family. Difficult on my emotions.
And every time you have a relapse it just makes you a little more anxious knowing that it’s happening all over again.
In 2019, I relapsed again. My doctor and I had talked about CABLIVI and thought that I should give it a shot if I was okay with that.
With the CABLIVI, my platelet level came up within 4 days. I don’t like being in the hospital, just like everyone else. My stay at the hospital was only for 6 days.
*CABLIVI was tested in a clinical study of 145 adults with aTTP/iTTP. 72 people were given CABLIVI, plasma exchange (PEX), and immunosuppressive therapy vs 73 people who were given placebo (an injection without any medicine), PEX, and immunosuppressive therapy. Both groups received either CABLIVI or placebo after their daily PEX, and then for 30 days after. Some people received more treatment (up to 28 additional days) based on their doctor’s decision. After treatment was stopped, everyone was followed by their doctor for 28 more days.*
Once you leave the hospital, having to take CABLIVI at home, I felt confident doing it at home because of the training that I got while in the hospital.
*Injection site reactions such as rash, bleeding, and itching may occur. Please remember that this video shares only Heather’s experience and that every patient’s experience is unique.*
The only side effects were a little bruising on the belly from the injection site.
*The most common side effects include nosebleed, headache, and bleeding gums. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.*
While taking CABLIVI, I did not experience any relapses, and I have not experienced any relapses 28 days after taking CABLIVI.
*Significantly fewer people had another episode of aTTP/iTTP that required starting PEX again within the full study period (while taking CABLIVI and 28 days after stopping CABLIVI) in the CABLIVI group vs the placebo group: 13% receiving CABLIVI (9 people) vs
38% receiving placebo (28 people). Individual results may vary.*
So I’ve lived with aTTP since 2007 and as long as I’m feeling good and can do things, I want to be out, enjoying the outdoors, sitting outside underneath the stars, and getting back to my girls.
Even though I know a relapse is possible at any time, I’m confident in knowing that CABLIVI will be there.
This was Heather’s personal experience with CABLIVI. Every patient’s experience is unique and individual results will vary. If you’re interested in learning more, please speak with your doctor about the potential benefits and risks of treatment with CABLIVI and whether CABLIVI may be right for you.
INDICATION AND IMPORTANT SAFETY INFORMATION
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Who should not take CABLIVI?
Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
Meet James and Dr Masias
“It’s the first time I heard of anything specific for aTTP. It lets me know someone is trying to figure out how to help.”
James, real patient. Individual results may vary. James is being compensated by Sanofi.
CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult patients with acquired Thrombotic Thrombocytopenic Purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Please stay tuned for the Important Safety Information at the end of this video.
[James]
I’m James. I’m a husband to a wonderful wife, father to three amazing kids. I’m a carpenter and woodworker, avid reader, always on a constant quest for knowledge. I’m a survivor, but most of all I’m a fighter, and this is my aTTP experience.
Back in 2015, I was, you know, delivering furniture for a company, started to feel a little bit of pain in my right abdomen, didn’t really think about it. As we started doing the first few deliveries, that pain intensified and, you know, my wife, she got to the point where, okay, you need to go to the hospital find out what’s going on. So, went to the hospital, was sent home, said they couldn’t find anything wrong with me. They really couldn’t explain the pain at that point. That feeling of dread, really, because I had no idea what was going on. So went home, and then ended up back in the ER and this point started noticing that, you know, my eyes became yellow, and my platelet level had dropped significantly. Hematologist ends up coming in, she had sent out for this one test, and it was a ADAMTS13 test. That’s when I was diagnosed with aTTP, and of course I never heard of it. I had no clue what I was dealing with, what was going on, and that’s when it became a battle.
[Dr Masias]
I am Dr Masias, and I have years of experience treating patients with aTTP. aTTP is a rare, potentially life-threatening disorder, which is why it’s so important to diagnose it early and treat it right away. Platelets are important components of blood that help stop bleeding when injury occurs. One of the ways the body can regulate platelet activity indirectly is via a protein called ADAMTS13 and von Willebrand factor. Normally, ADAMTS13 helps cut up von Willebrand factor. When you have aTTP, your immune system makes antibodies that attack ADAMTS13, preventing it from cutting the von Willebrand factor strands. When von Willebrand factor strands get too long, lots of platelets clump around them and those platelets can become blood clots that become stuck in the tiny blood vessels in the body. These clots can block the flow of blood to important organs such as the brain, heart, or kidneys. And this can cause serious health problems such as organ damage, stroke, or a heart attack.
It’s important to know what symptoms to look for. Low platelets can lead to bleeding from your gums and nose, bruises, petechiae, which are red dots that we see on the legs, and blood in the urine. Other symptoms that are common are chest pain, abdominal pain, confusion, tiredness, fatigue, and jaundice. These are some of the symptoms that I look for when I diagnose a patient with aTTP.
[James]
In 2019 my platelets dropped again and I had to go back into the hospital and this is when I was introduced to CABLIVI. It’s the first time I’ve heard of anything specific for aTTP. It lets me know that somebody is trying to work on this and trying to figure out how to help.
*CABLIVI was tested in a clinical study of 145 adults with aTTP/iTTP. 72 people were given CABLIVI, plasma exchange (PEX), and immunosuppressive therapy vs 73 people who were given placebo (an injection without any medicine), PEX, and immunosuppressive therapy. Both groups received either CABLIVI or placebo after their daily PEX, and then for 30 days after. Some people received more treatment (up to 28 additional days) based on their doctor’s decision. After treatment was stopped, everyone was followed by their doctor for 28 more days.*
[Dr Masias]
There are a few components when treating patients with aTTP with CABLIVI. Plasma exchange, also called plasmapheresis, is a process in which we take what a patient has a lot of, in this case antibodies against ADAMTS13, and it’s gonna also help us give the patient what they have little of, in this case ADAMTS13. Immunosuppression is going to help us control your immune system that is overactive when you have an episode of aTTP. CABLIVI, when used in combination with plasma exchange and immunosuppressive therapy, is gonna help prevent the formation of these very dangerous blood clots by preventing the interaction between von Willebrand factor and platelets.
I always talk to my patients about the potential side effects of CABLIVI. I believe in adding CABLIVI as soon as possible to all suitable adult patients with aTTP.
[James]
My platelet level went up when I had a CABLIVI in combination with my PEX and my immunosuppressant therapy. I didn’t experience any relapses while taking CABLIVI or for 28 days after. My doctor continues to monitor my blood work.
*Significantly fewer people had another episode of aTTP/iTTP that required starting PEX again within the full study period (while taking CABLIVI and 28 days after stopping CABLIVI) in the CABLIVI group vs the placebo group: 13% receiving CABLIVI (9 people) vs 38% receiving placebo (28 people). Individual results may vary.*
[Dr Masias]
I can’t stress enough the importance of a patient being educated on their disease, and I think it’s important for patients to know if these symptoms are related to their disease or this is something else that we need to diagnose and treat separately. By providing patients with education and being available to them, I think they can improve so much. It’s important that you discuss with your doctor if you think you’re a candidate for this medication.
[James]
Coming across CABLIVI was huge to me. My purpose to exist is to help educate others about aTTP. My oldest daughter, you know, she looked at me, you know, the one time and said you know you’re fighting this and you’re not giving up, you’re like you’re taking it on, you really are, you know, my superhero. That my kids see me like that is awesome to me. It really, it really inspires me. That’s my biggest goal to help whoever I can, however I can as far as aTTP.
This was James’s personal experience with CABLIVI. Every patient’s experience is unique and individual results will vary. If you’re interested in learning more, please speak with your doctor about the potential benefits and risks of treatment with CABLIVI and whether CABLIVI may be right for you.
INDICATION AND IMPORTANT SAFETY INFORMATION
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Who should not take CABLIVI?
Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
CABLIVI, in combination with PEX and immunosuppression, can help you take on aTTP/iTTP with confidence
CABLIVI treatment starts in the hospital
Claims are based on a clinical trial with 145 aTTP/iTTP patients, of which 72 obtained CABLIVI with plasma exchange and immunosuppression. The remaining 73 patients got placebo (injection without active medicine) with plasma exchange and immunosuppression. Both groups got either CABLIVI or placebo during daily plasma exchange therapy and for 30 days afterward. After treatment was stopped, everyone was followed by their doctor for 28 more days. Study showed that patients treated with CABLIVI achieved normal platelet count faster than patients in the placebo group. Also, 87% of CABLIVI-treated patients were free of relapses during the treatment period and for 28 days after versus 62% of patients treated with placebo.
*aTTP is also known as iTTP. You and your healthcare team can use either term.
aTTP/iTTP=acquired/immune-mediated thrombotic thrombocytopenic purpura.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
IMPORTANT SAFETY INFORMATION AND INDICATIONS
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Who should not take CABLIVI?
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Please see full Prescribing Information.
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Who should not take CABLIVI?
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Please see full Prescribing Information.
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Who should not take CABLIVI?
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Please see full Prescribing Information.
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Who should not take CABLIVI?
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Please see full Prescribing Information.
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Who should not take CABLIVI?
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Please see full Prescribing Information.
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Who should not take CABLIVI?
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
What should I tell my healthcare team before starting CABLIVI?
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
What are the possible side effects of CABLIVI?
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
What is CABLIVI?
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Please see full Prescribing Information.
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs.